A Phase 3 interventional study of Bimatoprost (SR) in Open-Angle Glaucoma and Ocular Hypertension, sponsored by AbbVie. Completed at 108 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.
Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 24th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
Amneal Pharmaceuticals, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 9 · Phase 4 12
First in 2007; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 515 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 169 across the 29 interventional studies. Of the 27 that completed or were terminated, 23 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 29 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 8th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 50th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
1 of the studies testing bimatoprost in Glaucoma, Open-Angle that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, from their registry updates:
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Eye: Participants will receive 1 - 3 Cycles of Bimatoprost SR administrations of Dose A Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or one administration of Bimatoprost SR.
Drug: Bimatoprost (SR)
Study Eye: Participants received 1 - 3 Cycles of Bimatoprost SR administrations of Dose B Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or one administration of Bimatoprost SR.
Drug: Bimatoprost (SR)
Study Eye: Cycles 1 - 3 administrations through the PRN treatment period. Fellow Eye: Standard of care or Bimatoprost SR.
Time to Retreatment or Rescue Administered for Intraocular Pressure (IOP)
The duration of effect for Bimatoprost SR was evaluated by assessing the time to second administration of Bimatoprost SR or first rescue treatment (i.e., initiation of intermittent \[use of rescue IOP-lowering medication until the subject became eligible for and received an additional Bimatoprost SR administration\] or permanent rescue treatment), whichever occurred first, after the first administration in the study eye (SE).
Time frame: Up to 48 months
Probability of Not Receiving Second Administration or Rescue
The Kaplan-Meier method was used to estimate the cumulative survival probabilities (i.e., probability of not receiving the re-administration or rescue treatment) at time intervals across the duration of the study.
Time frame: Up to 48 months
Number of Patients Experiencing a Treatment Emergent Adverse Event (TEAE)
The number of patients who experienced one or more TEAE during the 48 month treatment period.
Time frame: Baseline up to 48 months
| Milestone | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR |
|---|---|---|
| Started | 446 | 62 |
| Number of subjects treated | 441 | 62 |
| Number of subjects enrolled but not treated | 5 | 0 |
| Completed | 363 | 50 |
| Not completed | 83 | 12 |
| Withdrew: Adverse event | 16 | 4 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Withdrawal by subject | 32 | 6 |
| Withdrew: Lost to follow-up | 15 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Not disclosed | 14 | 2 |
| Withdrew: Subjects with missing study completion status (completed study required last visit of month 48) | 1 | 0 |
The duration of effect for Bimatoprost SR was evaluated by assessing the time to second administration of Bimatoprost SR or first rescue treatment (i.e., initiation of intermittent \[use of rescue IOP-lowering medication until the subject became eligible for and received an additional Bimatoprost SR administration\] or permanent rescue treatment), whichever occurred first, after the first administration in the study eye (SE).
| days | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR |
|---|---|---|
| Time to Retreatment or Rescue Administered for Intraocular Pressure (IOP) | 421 (374 to 488) | 365 (200 to 476) |
The Kaplan-Meier method was used to estimate the cumulative survival probabilities (i.e., probability of not receiving the re-administration or rescue treatment) at time intervals across the duration of the study.
| cumulative probability | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR |
|---|---|---|
| 180 Days | 0.752 (0.709 to 0.790) | 0.707 (0.575 to 0.804) |
| 360 Days | 0.589 (0.541 to 0.634) | 0.522 (0.390 to 0.639) |
| 540 Days | 0.409 (0.361 to 0.456) | 0.357 (0.236 to 0.480) |
| 720 Days | 0.313 (0.268 to 0.359) | 0.301 (0.188 to 0.422) |
| 900 Days | 0.268 (0.225 to 0.313) | 0.301 (0.188 to 0.422) |
| 1080 Days | 0.254 (0.212 to 0.299) | 0.251 (0.143 to 0.374) |
| 1260 Days | 0.226 (0.183 to 0.272) | 0.251 (0.143 to 0.374) |
| 1440 Days | 0.226 (0.183 to 0.272) | 0.251 (0.143 to 0.374) |
The number of patients who experienced one or more TEAE during the 48 month treatment period.
| Participants | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR |
|---|---|---|
| Number of Patients Experiencing a Treatment Emergent Adverse Event (TEAE) | 356 | 54 |
Collected over All-cause mortality and adverse event tables include events reported from time informed consent was signed to the end of study. The median time on follow-up was 1119.5 days for the 10 ug Bimatoprost SR group and 1242 days for the 15 ug Bimatoprost SR group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 ug Bimatoprost SR | 7/446 (1.6%) | 80/446 (17.9%) | 278/446 (62.3%) |
| 15 ug Bimatoprost SR | 2/62 (3.2%) | 12/62 (19.4%) | 40/62 (64.5%) |
| Event | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR |
|---|---|---|
| CORNEAL OEDEMAEye disorders | 3/446 | 3/62 |
| FALLInjury, poisoning and procedural complications | 5/446 | 2/62 |
| CORNEAL ENDOTHELIAL CELL LOSSEye disorders | 3/446 | 1/62 |
| INTESTINAL PERFORATIONGastrointestinal disorders | 0/446 | 1/62 |
| NAUSEAGastrointestinal disorders | 0/446 | 1/62 |
| RECTAL PERFORATIONGastrointestinal disorders | 0/446 | 1/62 |
| VOMITINGGastrointestinal disorders | 0/446 | 1/62 |
| DEATHGeneral disorders | 2/446 | 1/62 |
| COVID-19Infections and infestations | 2/446 | 1/62 |
| COVID-19 PNEUMONIAInfections and infestations | 0/446 | 1/62 |
| Event | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR |
|---|---|---|
| CONJUNCTIVAL HYPERAEMIAEye disorders | 89/446 | 12/62 |
| INTRAOCULAR PRESSURE INCREASEDInvestigations | 88/446 | 9/62 |
| CORNEAL ENDOTHELIAL CELL LOSSEye disorders | 66/446 | 12/62 |
| DRY EYEEye disorders | 41/446 | 8/62 |
| HYPERTENSIONVascular disorders | 45/446 | 7/62 |
| VISUAL FIELD DEFECTEye disorders | 26/446 | 6/62 |
| COVID-19Infections and infestations | 41/446 | 4/62 |
| EYE PAINEye disorders | 19/446 | 5/62 |
| CONJUNCTIVITISInfections and infestations | 20/446 | 5/62 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 6/446 | 5/62 |
Full Analysis Set
| Age, Continuous(years) | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR | Total |
|---|---|---|---|
| Mean | 62.5 ± 10.89 | 67.5 ± 11.01 | 65 ± 10.95 |
| Age, Customized(participants) | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR | Total |
|---|---|---|---|
| < 45 years | 22 | 3 | 25 |
| 45 - 65 years | 235 | 24 | 259 |
| > 65 years | 184 | 35 | 219 |
| Sex: Female, Male(Participants) | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR | Total |
|---|---|---|---|
| Female | 239 | 31 | 270 |
| Male | 202 | 31 | 233 |
| Ethnicity (NIH/OMB)(Participants) | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR | Total |
|---|---|---|---|
| Hispanic or Latino | 50 | 5 | 55 |
| Not Hispanic or Latino | 391 | 57 | 448 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 10 ug Bimatoprost SR | 15 ug Bimatoprost SR | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 66 | 5 | 71 |
| White | 360 | 53 | 413 |
| More than one race | 8 | 0 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 108 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Feb 2019 to primary completion in Aug 2025, 77 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 77 months is above that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimatoprost